Cancer Vaccines Markets

Description: Cancer vaccines have the potential to become a significant force in future cancer treatments. In 2010, Dendreon’s Provenge became the first cancer vaccine approved by the FDA, generating renewed interest and support for this type of cancer immune therapy. Cancer vaccines can be divided into six main categories: antigen/adjuvant vaccines, DNA vaccines, vector-based vaccines, tumor cell vaccines, dendritic cell vaccines and anti-idiotype vaccines. This relatively new commercial market for cancer vaccines is poised to dramatically increase to over $7 billion by 2015.

The purpose of this TriMark Publications report is to supply comprehensive information on the developing market for cancer vaccines. This study surveys almost all of the companies known to be marketing, manufacturing, or developing cancer vaccines in the world, providing in-depth analysis of the current and emerging technologies in the cancer vaccines market. Each company is extensively examined, with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company’s market position.

Moreover, this report provides detailed discussions of cancer vaccines funding trends, intellectual property, market opportunities, research collaborations, partnership activities, regulatory issues and guidelines for establishing new ventures. Detailed tables and charts with sales forecasts and market share data are also included.

Contents:

1. Overview
   1.1 About this Report
   1.2 Scope of the Report
   1.3 Objectives
   1.4 Methodology
   1.5 Executive Summary

2. Overview of Cancer
   2.1 Cancer Statistics
   2.2 The Cost of Cancer
   2.3 Cancers Being Targeted by Vaccine Therapies: Overview of Disease and Market

3. Introduction to Cancer Vaccines
   3.1 Overview of the Types of Cancer Vaccines
   3.2 Antigen/Adjuvant Vaccines
   3.3 DNA Vaccines
   3.4 Vector-based Vaccines
   3.5 Tumor Cell Vaccines
   3.6 Dendritic Cell (DC) Vaccines
   3.7 Anti-Idiotype Vaccines

4. Prophylactic Vaccines on the Market and in Development
   4.1 Cervical Cancer (HPV)
   4.2 Prophylactic Breast Cancer Vaccine in Development

5. Therapeutic Vaccines on the Market and in Development
   5.1 Breakthroughs in the Cancer Vaccine Market: Vaccines on the Market
   5.2 Vaccines in Development (by Type of Vaccine)

6. Challenges and Issues in Cancer Vaccine Development
   6.1 Eliciting Appropriate Immune Response Against Cancer
   6.2 Clinical Trial Design
   6.3 Combination Therapies

7. Regulatory Issues
7.1 Pharmaceutical Product Regulation
7.2 New Drug Application (NDA) or Biologics License Application (BLA)
7.3 Post-Approval Phase
7.4 Fast-Track Review
7.5 Orphan Drug Designation and Exclusivity
7.6 What Regulatory Guidance Is Needed for Companion Biomarkers?
7.7 Oncology Biomarker Qualification Initiative
7.8 IRB Approval in Clinical Trials
7.9 U.S. Patent and Trademark Office (USPTO)

8. Trends Affecting the Cancer Vaccine Market
8.1 Screening and Cancer Detection
8.2 Public Perception of Vaccines
8.3 Insurance Issues
8.4 New Technological and Scientific Developments
8.5 Personalized Medicine

9. Business Landscape
9.1 Technology and Market Trends
9.2 M&A Activity
9.3 Partnering
9.4 Competitive Situation
9.5 Intellectual Property Rights
9.6 Industry Challenges and Strategic Recommendations for Commercialization
9.7 Opportunities and Strategic Recommendations
9.8 Requirements for a Successful Cancer Vaccine Products Industry

10. Company Profiles
10.1 Advaxis
10.2 Agenus (formerly Antigenics)
10.3 AlphaVax
10.4 Antigen Express
10.5 Apthera
10.6 Argos Therapeutics
10.7 AVAX Technologies
10.8 Bavarian Nordic
10.9 Bellicum Pharmaceuticals
10.10 BioSante Pharmaceuticals
10.11 Biovest International
10.12 CellDex Therapeutics
10.13 CG Therapeutics
10.14 CureVac
10.15 DanDrit Biotech
10.16 Dendreon
10.17 EMD Serono
10.18 Geron
10.19 GlaxoSmithKline
10.20 Globelimmune
10.21 Immatics Biotechnologies
10.22 ImmunoCellular Therapeutics
10.23 Immunovaccine
10.24 Inovio Pharmaceuticals
10.25 KAEL-Gemvax
10.26 MannKind
10.27 Mologen AG
10.28 NewLink Genetics Corporation
10.29 Northwest Biotherapeutics
10.30 NovaRx
10.31 Oxford BioMedica
10.32 Prima BioMed
10.33 Scancell
10.34 Transgene
10.35 Trimed Biotech
INDEX OF FIGURES

Figure 2.1: Estimates of National Expenditures for Cancer Care in 2006 by Cancer Site
Figure 2.2: Person-Years of Life Lost (PYLL) in the U.S. Due to Cancer, Male, 2006
Figure 2.3: Person-Years of Life Lost (PYLL) in the U.S. Due to Cancer, Female, 2006
Figure 3.1: Antigen Presentation
Figure 3.2: Antigen/Adjuvant Cancer Vaccine Immunotherapy Process
Figure 3.3: DNA Cancer Vaccine Immunotherapy Process
Figure 3.4: Viral Vector Cancer Vaccine Immunotherapy Process
Figure 3.5: Modified Tumor Cell Cancer Vaccines
Figure 3.6: Dendritic Cell Vaccination Process
Figure 3.7: Schematic of Anti-idiotype Antibodies for Cancer Vaccines
Figure 5.1: New Therapeutic Cancer Vaccines Entering Clinical Study Per Year During 1990-2006

INDEX OF TABLES

Table 2.1: Estimated New Cancer Cases and Deaths in the U.S. by Sex for all Cancer Sites, 2010
Table 2.2: Estimated New Cancer Cases and Deaths for Ten Leading Cancer Sites in the U.S. in 2010, by Sex
Table 2.3: Worldwide Number of New Cancer Cases and Deaths by Leading Cancer Sites and by Level of Economic Development, 2008
Table 2.4: Number of New Cancer Cases and Deaths by World Area, 2008
Table 2.5: Estimated Annual Costs of Cancer in the U.S. in Billions, 2008
Table 2.6: Cancer Vaccines in the Pipeline, by Cancer Type
Table 3.1: Infectious Agents Involved in Cancer
Table 3.2: Cancer Vaccine Technologies
Table 3.3: Antigens Commonly Found in Cancer Vaccines
Table 3.4: Adjuvants Commonly Found in Cancer Vaccines
Table 4.1: Cervical Cancer Vaccines on the Market
Table 5.1: Therapeutic Vaccines on the Market
Table 5.2: Pipeline of Therapeutic Cancer Vaccines, by Type of Vaccine
Table 5.3: Antigen/Adjuvant Vaccines in Development
Table 5.4: DNA and RNA Vaccines in Development
Table 5.5: Vector-based Vaccines in Development
Table 5.6: Autologous Tumor Cell Vaccines in Development
Table 5.7: Allogeneic Tumor Cell Vaccines in Development
Table 5.8: Dendritic Cell Vaccines in Development
Table 5.9: Anti-Idiotype Vaccines in Development
Table 5.10: Competitors with Phase III Cancer Vaccine Candidates in Their Pipelines
Table 6.1: Mechanisms of Immune Evasion by Cancers
Table 6.2: Key Recommendations for Cancer Vaccine Clinical Trial Design
Table 6.3: Challenges and Strategic Recommendations for Clinical Trial Design
Table 6.4 Combination Strategies to Enhance a Vaccine’s Anti-Tumor T-Cell Response
Table 7.1: Focus Areas for the FDA Critical Path Initiative
Table 9.1: Industry Challenges and Strategic Recommendations for Commercialization
Table 9.2: Required Elements of a Manufacturing Facility
Table 9.3: CMO Qualification Audit-Points to Investigate
Table 9.4: Strategies for Marketing Cancer Vaccines

Ordering:

Order Online - http://www.researchandmarkets.com/reports/1656802/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Cancer Vaccines Markets
Web Address: http://www.researchandmarkets.com/reports/1656802/
Office Code: SCD22DJ6

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 10 Users</td>
<td></td>
<td>USD 5000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 7500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ________________________________ Last Name: ________________________________
Email Address: * ________________________________
Job Title: ________________________________
Organisation: ________________________________
Address: ________________________________
City: ________________________________
Postal / Zip Code: ________________________________
Country: ________________________________
Phone Number: ________________________________
Fax Number: ________________________________

* Please refrain from using free email accounts when ordering (e.g., Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World